More than 25,000 hematopoietic stem cell transplantations (HSCTs) are performed each
year for the treatment of lymphoma, leukemia, immune-deficiency illnesses, congenital …

PURPOSE: To review recent advances in peripheral-blood progenitor-cell (PBPC)
transplantation in order to define the optimal cell dose required for autologous and …

This line of reasoning—focusing on human capability—contrasts with the idea that health
care is special because of its impact on equality of opportunity. 6 It also differs from the …

PURPOSE: To determine the prevalence of psychiatric disorders during hospitalization for
hematopoietic stem-cell transplantation (SCT) and to estimate their impact on hospital length …

The purpose of this article was to examine historic institutional autologous stem cell
mobilization practices and evaluate factors influencing mobilization failure and kinetics. In …

As more efficient agents for stem cell mobilization are being developed, there is an urgent
need to define which patient population might benefit from these novel drugs. For a precise …

Peripheral blood cells are increasingly used in place of bone marrow as a source of
hematopoietic stem cells for allogeneic transplantation. The relative efficacy of these 2 …

PURPOSE: Controversy exists as to whether the incidence of graft-versus-host disease
(GVHD) is increased after peripheral-blood stem-cell transplantation (PBSCT) when …

Purpose Interactions between the chemokine receptor CXCR4 and its ligand stromal
derived factor-1 regulate hematopoietic stem-cell trafficking. AMD3100 is a CXCR4 …

PURPOSE: To compare hematologic recovery in patients receiving allogeneic blood cell
transplantation (BCT) with those receiving allogeneic bone marrow transplantation (BMT) …